Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C18H17Cl2FN4OS.ClH |
Molecular Weight | 463.784 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CN1N=CC(Cl)=C1C2=C(Cl)SC(=C2)C(=O)N[C@H](CN)CC3=CC=CC(F)=C3
InChI
InChIKey=YFQJOPFTGMHYNV-YDALLXLXSA-N
InChI=1S/C18H17Cl2FN4OS.ClH/c1-25-16(14(19)9-23-25)13-7-15(27-17(13)20)18(26)24-12(8-22)6-10-3-2-4-11(21)5-10;/h2-5,7,9,12H,6,8,22H2,1H3,(H,24,26);1H/t12-;/m0./s1
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C18H17Cl2FN4OS |
Molecular Weight | 427.323 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/24978597Curator's Comment: Description was created based on several sources, including
http://www.bloodjournal.org/content/118/21/1856 http://adisinsight.springer.com/drugs/800033693
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24978597
Curator's Comment: Description was created based on several sources, including
http://www.bloodjournal.org/content/118/21/1856 http://adisinsight.springer.com/drugs/800033693
Afuresertib (GSK2110183 ) is an orally bioavailable inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineoplastic activity. Afuresertib binds to and inhibits the activity of Akt, which may result in inhibition of the PI3K/Akt signaling pathway and tumor cell proliferation and the induction of tumor cell apoptosis. Activation of the PI3K/Akt signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K/Akt signaling may contribute to tumor resistance to a variety of antineoplastic agents. Preclinically, AKT inhibition by afuresertib can reverse platinum resistance in ovarian cancer cell lines isolated from patients with platinum-resistant ovarian cancer. Afuresertib is well tolerated and demonstrates clinical activity as monotherapy in heavily pretreated MM patients. Is in phase II clinical trials for Chronic lymphocytic leukaemia; Haematological malignancies; Histiocytosis.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL4282 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24978597 |
0.08 nM [Ki] | ||
Target ID: CHEMBL2431 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24978597 |
2.0 nM [Ki] | ||
Target ID: CHEMBL4816 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24978597 |
2.6 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
949 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25075128/ |
150 mg 1 times / day multiple, oral dose: 150 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
AFURESERTIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
554 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25075128/ |
100 mg 1 times / day multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
AFURESERTIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
531 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25075128/ |
125 mg 1 times / day multiple, oral dose: 125 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
AFURESERTIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
13425 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25075128/ |
150 mg 1 times / day multiple, oral dose: 150 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
AFURESERTIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
6782 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25075128/ |
100 mg 1 times / day multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
AFURESERTIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
7405 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25075128/ |
125 mg 1 times / day multiple, oral dose: 125 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
AFURESERTIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
PubMed
Title | Date | PubMed |
---|---|---|
Discovery of novel AKT inhibitors with enhanced anti-tumor effects in combination with the MEK inhibitor. | 2014 |
|
Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma. | 2015 Jan |
|
A phase IIa study of afuresertib, an oral pan-AKT inhibitor, in patients with Langerhans cell histiocytosis. | 2017 May |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25075128
Seventy-three patients were treated at doses ranging from 25 to 150 mg per day. The MTD was established at 125 mg per day
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24978597
Afuresertib inhibits the kinase activity of the E17K AKT1 mutant protein with EC50 of 0.2 nM. Afuresertib shows a concentration-dependent effect on multiple AKT substrate phosphorylation levels, including GSK3b, PRAS40, FOXO and Caspase 9. Overall 65% of the hematological cell lines are sensitive to afuresertib (EC50 < 1 uM).
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:45:46 GMT 2023
by
admin
on
Fri Dec 15 16:45:46 GMT 2023
|
Record UNII |
0FC27E442O
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C61074
Created by
admin on Fri Dec 15 16:45:46 GMT 2023 , Edited by admin on Fri Dec 15 16:45:46 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DBSALT002037
Created by
admin on Fri Dec 15 16:45:46 GMT 2023 , Edited by admin on Fri Dec 15 16:45:46 GMT 2023
|
PRIMARY | |||
|
ZZ-03
Created by
admin on Fri Dec 15 16:45:46 GMT 2023 , Edited by admin on Fri Dec 15 16:45:46 GMT 2023
|
PRIMARY | |||
|
DTXSID20146712
Created by
admin on Fri Dec 15 16:45:46 GMT 2023 , Edited by admin on Fri Dec 15 16:45:46 GMT 2023
|
PRIMARY | |||
|
1047645-82-8
Created by
admin on Fri Dec 15 16:45:46 GMT 2023 , Edited by admin on Fri Dec 15 16:45:46 GMT 2023
|
PRIMARY | |||
|
300000044612
Created by
admin on Fri Dec 15 16:45:46 GMT 2023 , Edited by admin on Fri Dec 15 16:45:46 GMT 2023
|
PRIMARY | |||
|
0FC27E442O
Created by
admin on Fri Dec 15 16:45:46 GMT 2023 , Edited by admin on Fri Dec 15 16:45:46 GMT 2023
|
PRIMARY | |||
|
46843056
Created by
admin on Fri Dec 15 16:45:46 GMT 2023 , Edited by admin on Fri Dec 15 16:45:46 GMT 2023
|
PRIMARY | |||
|
CHEMBL2219422
Created by
admin on Fri Dec 15 16:45:46 GMT 2023 , Edited by admin on Fri Dec 15 16:45:46 GMT 2023
|
PRIMARY | |||
|
C142902
Created by
admin on Fri Dec 15 16:45:46 GMT 2023 , Edited by admin on Fri Dec 15 16:45:46 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |